摘要
目的:探讨兔抗胸腺细胞球蛋白联合环孢素对重型再生障碍性贫血患者疗效及血管内皮生长因子(vascular endothelial growth factor,VEGF)、白细胞介素(IL)-17及IL-6表达的影响。方法:选取2015年1月-2020年5月本院收治的60例重型再生障碍性贫血患者的临床资料进行回顾性分析。根据治疗方法将患者分为对照组(n=30)和研究组(n=30)。对照组进行环孢素治疗,观察组在对照组基础上联合兔抗胸腺细胞球蛋白治疗。比较两组临床疗效、VEGF、IL-17、IL-6水平、血象指标水平和不良反应。结果:研究组治疗总有效率高于对照组(P<0.05)。治疗后,观察组血清IL-17与IL-6水均低于对照组,而VEGF水平高于对照组(P<0.05)。治疗后,两组血红蛋白(Hb)、血小板计数(BPC)及白细胞计数(WBC)水平均高于治疗前,且研究组均高于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:兔抗胸腺细胞球蛋白联合环孢素治疗重型再生障碍性贫血患者的效果显著,可明显改善VEGF、IL-17、IL-6水平和血象指标,且安全性较高,值得应用。
Objective:To explore the effect of Rabbit Antithymocyte Globulin combined with Cyclosporine on severe aplastic anemia patients and the effect of vascular endothelial growth factor (VEGF),interleukin (IL)-17 and IL-6 expression.Method:The clinical data of 60 patients with severe aplastic anemia admitted to our hospital from January 2015 to May 2020 were retrospectively analyzed.They were divided into control group (n=30) and study group (n=30) according to the treatment methods.The control group was treated with Cyclosporine,and the study group was treated with Rabbit Antithymocyte Globulin on the basis of the control group.Clinical efficacy,levels of VEGF,IL-17 and IL-6,blood index level and adverse reactions were compared between two groups.Result:The total effective rate of the study group was higher than that of the control group (P<0.05).After treatment,serum IL-17 and IL-6 in the study group were lower than those in the control group,while VEGF level was higher than that in the control group (P<0.05).After treatment,hemoglobin (Hb),blood platelet count (BPC) and white blood cell count (WBC) levels in two groups were higher than those before treatment,and the study group were higher than the control group (P<0.05).There was no statistically significant difference in the incidence of adverse reactions between two groups (P>0.05).Conclusion:Rabbit Antithymocyte Globulin combined with Cyclosporine has significant effect on patients with severe aplastic anemia.It can significantly improve the level of VEGF,IL-17,IL-6 and blood indicators,and the safety is higher,which is worthy of application.
作者
林春燕
陈琼
吴挺柏
李丽羽
黄春辉
LIN Chunyan;CHEN Qiong;WU Tingbo;LI Liyu;HUANG Chunhui(Zhongshan Hospital Affiliated to Sun Yat-sen University,Zhongshan 528400,China;不详)
出处
《中国医学创新》
CAS
2020年第33期38-41,共4页
Medical Innovation of China
